Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.56 |
| ▸ | DBF4 | Q9UBU7 | 9/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707390 | 0.89 | CDC7 (0.58) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL3709672 | 0.83 | CDC7 (0.52) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL3702956 | 0.81 | CDC7 (0.59) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL3712656 | 0.80 | CDC7 (0.50) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL2184826 | 0.80 | CDC7 (0.58) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL3712683 | 0.79 | CDC7 (0.48) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL455876 | 0.78 | CDC7 (0.62) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL3712724 | 0.78 | CDC7 (0.55) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL3714429 | 0.78 | LMNA (0.48) | CDC7DBF4KDM4EALDH1A1LMNA | |
| SCHEMBL1984283 | 0.77 | CDC7 (0.64) | CDC7DBF4KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2338887-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | CDC7 3107/4885DBF4 3228/4885KDM4E 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.